To deter opioid abuse and addiction through the development of high-quality, evidence-based opioid analgesic prescribing guidelines, and for other purposes.
USA115th CongressHR-6133| House
| Updated: 6/19/2018
Mark Meadows
Republican Representative
North Carolina
Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Informing Opioid Prescribing Through Evidence-Based Guidelines Act of 2018 This bill requires the Food and Drug Administration to develop evidence-based opioid prescribing guidelines for certain acute pain treatment.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Health
Administrative law and regulatory proceduresCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyDrug trafficking and controlled substancesFood and Drug Administration (FDA)Government studies and investigationsHealth care costs and insuranceHealth care coverage and accessHealth promotion and preventive carePrescription drugsPublic participation and lobbyingRetail and wholesale trades
To deter opioid abuse and addiction through the development of high-quality, evidence-based opioid analgesic prescribing guidelines, and for other purposes.
USA115th CongressHR-6133| House
| Updated: 6/19/2018
Informing Opioid Prescribing Through Evidence-Based Guidelines Act of 2018 This bill requires the Food and Drug Administration to develop evidence-based opioid prescribing guidelines for certain acute pain treatment.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Mark Meadows
Republican Representative
North Carolina
Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative law and regulatory proceduresCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyDrug trafficking and controlled substancesFood and Drug Administration (FDA)Government studies and investigationsHealth care costs and insuranceHealth care coverage and accessHealth promotion and preventive carePrescription drugsPublic participation and lobbyingRetail and wholesale trades